CD274 and head and neck squamous cell carcinoma: In 2021, Julian et al. [10] reported the results of an open phase Ib/IIa study combining an anti-PD-L1 agent (durvalumab) with MEDI0457 in 27 patients with R/M HNSCC and HPV-positive (Table 3).